

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

POSITIVE PROFIT ALERT

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) hereby informs the shareholders (the “**Shareholders**”) and potential investors of the Company that, based on the information currently available to the Group and its preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2021 (the “**Reporting Period**”), it is expected that the Group’s net profit will turn around during the Reporting Period as compared to the corresponding period in 2020. The Group is expected to record a net profit attributable to owners of the Company of approximately RMB900.0 million to RMB1,050.0 million during the Reporting Period (corresponding period in 2020: net loss attributable to owners of the Company of approximately RMB102.2 million). The net profit attributable to owners of the Company after deducting the non-recurring profit or loss during the Reporting Period is expected to be approximately RMB850.0 million to RMB1,000.0 million (corresponding period in 2020: net loss attributable to owners of the Company after deducting the non-recurring profit or loss of approximately RMB116.3 million). In addition, the Group is expected to record a revenue of approximately RMB2,000.0 million to RMB2,200.0 million for the Reporting Period (corresponding period in 2020 under Hong Kong Financial Reporting Standards: nil).

As far as the Board is aware, the profit growth with a turnaround for the Reporting Period as compared to the corresponding period in 2020 was mainly due to the increased sales of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia) in China and abroad.

The Board hereby reminds the Shareholders and potential investors of the Company that the information set out in this announcement is based on an assessment with reference to the information currently available to the Group and has not been reviewed or audited by the audit committee of the Company and the independent auditors. The Group is still finalizing the interim results for the six months ended June 30, 2021 (the “**Interim Results**”), which are subject to adjustments (if necessary). The Interim Results may differ from the data set out in this announcement. Shareholders and potential investors of the Company are advised to read carefully the details of the Group’s Interim Results, which is expected to be published in late August 2021.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, July 16, 2021

As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.